Are Wall Street Analysts Predicting Amgen Stock Will Climb or Sink?

With a market cap of $153.4 billion, Amgen Inc. (AMGN) is a global leader in biotechnology, focusing on innovative human therapeutics across various therapeutic areas including oncology, cardiovascular disease, and neuroscience. With a robust portfolio of blockbuster drugs and a promising pipeline, the company continues to drive advancements in medicine, particularly through its biosimilars and cancer treatments.

Shares of the world's largest biotech drugmaker have underperformed the broader market over the past 52 weeks. AMGN has decreased 10.7% over this time frame, while the broader S&P 500 Index ($SPX) has gained 20.9%. However, AMGN stock has risen 10.8% on a YTD basis, outperforming SPX's 1.9% YTD gain.